Abstract 15 Table 1 Clinical outcomes in patients treated with glycoprotein IIb/IIIa-inhibitors according to arterial access site. Data are expressed in n (%); HR: Hazard ratio; CI: Confidence interval; *p-value 0.05
| Transfemoral PPCI | Transradial PPCI | |||
|---|---|---|---|---|
| No GP IIb/IIIa inhibitor n=652 | GP IIb/IIIa inhibitor n=169 | No GP IIb/IIIa inhibitor n=1369 | GP IIb/IIIa inhibitor n=179 | |
| 30 day mortality n (%) Adjusted HR (95% CI) | 53 (8.0) 1.00 | 21 (12.4) 2.04 (1.05–3.94)* | 25 (1.8) 1.00 | 4 (2.2) 1.27 (0.39–4.16) |
| 12 month mortality n (%) Adjusted HR (95% CI) | 77 (11.6) 1.00 | 24 (14.1) 1.48 (0.82–2.67) | 69 (4.9) 1.00 | 10 (5.5) 1.21 (0.58–2.51) |
| 30 day total bleeding n (%) Adjusted HR (95% CI) | 47 (7.1) 1.00 | 27 (15.9)* 2.05 (1.07–3.93)* | 29 (2.1) 1.00 | 8 (4.4) 1.93 (0.73–4.76) |
| 30 day arterial access site bleeding n (%) Adjusted HR (95% CI) | 13 (2.0) 1.00 | 12 (7.1)* 2.71 (1.00–7.37)* | 1 (0.1) N/A | 0 (0.0) N/A |